Navigation Links
CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis
Date:2/22/2010

upon the type of L.E.A.P.S. construct and ICBL used, CEL-SCI is able to direct the outcome of the immune response towards the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). Therefore, it would appear that the L.E.A.P.S. construct represents a chimeric peptide with bi-functional behavior.

Additional details including the full publication with color photomicrographs of tissue sections, tables and figures are available at http://dx.doi.org/10.1016/j.intimp.2009.12.016.

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its L.E.A.P.S. technology platform.  The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the S
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CEL-SCI Corporation Releases Letter to Shareholders
2. CEL-SCI Corporation Reports First Quarter 2010 Financial Results
3. CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference
4. CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
5. CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine
6. CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine
7. CEL-SCI Corporation Releases Letter to Shareholders
8. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
9. CEL-SCI Expands H1N1 Flu Virus Work
10. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
11. CEL-SCI Posts New Corporate Presentation to Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... May 6, 2015 /PRNewswire/ -- Concord Medical Services Holdings ... ), a leading specialty hospital management solution provider ... and diagnostic imaging centers in China ... a multi-year strategic development agreement with The University ... an internationally renowned cancer research, treatment and education ...
(Date:5/6/2015)... May 6, 2015 Neuralstem, Inc. (NYSE MKT: ... to develop small molecule and cell therapy treatments for ... Jonathan Lloyd Jones to the position of Chief ... Mr. Lloyd Jones brings to the ... business development experience.   Most recently, Mr. Lloyd Jones ...
(Date:5/6/2015)... First programme to ... rilpivirine   ViiV Healthcare today ... trial programme to evaluate the safety and efficacy ... as maintenance therapy for adult patients with HIV. ... evaluating 48 week viral suppression with a two ...
Breaking Medicine Technology:Concord Medical Services Signs Multi-year Strategic Collaboration Agreement with MD Anderson Cancer Center 2Concord Medical Services Signs Multi-year Strategic Collaboration Agreement with MD Anderson Cancer Center 3Concord Medical Services Signs Multi-year Strategic Collaboration Agreement with MD Anderson Cancer Center 4Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 2Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 3Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10
... Colo. , June 14 REO, a ... appointed Mark Notarfrancesco to the newly created ... role, Mark will direct all aspects of the company,s ...  Prior to joining REO, Mark served with Intel Corporation ...
... Covance Inc. (NYSE: CVD ) today announced that it will ... Wednesday, June 16, 2010 at 3:00 p.m. (ET) .  Investors may ... to register and download any necessary software, please log on 10 minutes early. ... Covance, with headquarters in Princeton, ...
Cached Medicine Technology:Mark Notarfrancesco Joins REO as VP Manufacturing Operations 2
(Date:5/6/2015)... 06, 2015 Established by the Arthritis ... the estimated 46 million Americans who suffer from arthritis. ... medications to alleviate their symptoms. Medicationdiscountcard.com is proud to ... patients money on the costs of these necessary prescriptions. ... to treat the pain and inflammation in the joints ...
(Date:5/6/2015)... 06, 2015 The Jefferson Awards ... to activating and celebrating public service, announced today ... Health, as an Outstanding Employee Volunteer Organization. Champions ... Awards Foundation, are dedicated to building a culture ... decade, Highmark Health has recognized employees who volunteer ...
(Date:5/6/2015)... Stout Industries is owned and operated by ... Texas fire departments. Stout Industries recently developed Fire-ground Injury ... to these fire safety devices. The departure lights are ... turned on. They light the area within 50 feet of ... the roof, preventing leg and ankle injuries. In 2013 ...
(Date:5/6/2015)... NH (PRWEB) May 06, 2015 Launch Corporation, ... has opened its new Nashua location at 17 Tanguay Avenue. ... will be the duo’s second Launch location in New England. ... their new team,” said Rob Arnold, founder, co-owner and CEO ... location and we look forward to seeing them continue to ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 The SGNY ... New York City, announced today that it was named ... for a presentation video produced on behalf of Intarcia ... the category of motion graphics. , The competition sponsored ... received over 6000 entries from 22 countries. The ...
Breaking Medicine News(10 mins):Health News:Medicationdiscountcard.com Provides Access to Drug Coupons for Arthritis Awareness Month 2Health News:Medicationdiscountcard.com Provides Access to Drug Coupons for Arthritis Awareness Month 3Health News:The Jefferson Awards Foundation Honors Highmark Health 2Health News:The Jefferson Awards Foundation Honors Highmark Health 3Health News:The Jefferson Awards Foundation Honors Highmark Health 4Health News:Kickstarter for FIRE Lights, the New Fire Safety Devices 2Health News:Jump Up and Celebrate: Launch Trampoline Park Opens in Nashua, NH 2Health News:The SGNY Group Wins Platinum Hermes Creative Award 2
... 23 Niutang Chemical, a leading,global manufacturer of ... Alan Turner to lead its new office in ... Ltd., Mr. Turner will,spearhead all of Nuitang,s sales ... acid. He will particularly focus on the company,s,fast-growing ...
... WellPoint, Inc. (NYSE:,WLP) today announced the appointment ... segment, effective July 8, 2008., In his ... WellPoint,s,Individual Business segment, which currently serves more than ... add the quality of experience and,strategic expertise that ...
... individuals had more advanced disease and were less likely ... News) -- Low socioeconomic status increases a cancer patient,s ... on almost 14,000 breast, prostate and colorectal patients in ... patients with low socioeconomic status had more advanced cancers ...
... discovery holds promise as a treatment target for this diverse ... Cancerous myeloma cells are so "addicted" to a gene known ... has revealed. , Reducing the activity of the gene by ... compromising other healthy activities, said scientists reporting in the current ...
... AFAM ) announced today that it is scheduled to ... of market on June 27,according to a preliminary list of ... B. Yarmuth, President and CEO of Almost Family, Inc., stated,"We ... end of June as,it will provide greater awareness and visibility ...
... Before Disaster ... Fans, Players and Coaches, CLEVELAND, June 23 The ... -- able to,detect hidden flaws or developed stress within Major ... -- will be introduced as,BatteryMate(TM) on June 27, 2008, at ...
Cached Medicine News:Health News:Niutang Recruits Seasoned Executive to Open U.K. Office 2Health News:WellPoint Appoints Raj G. Bal as President of Individual Business 2Health News:Poorer Patients Have Poorer Survival After Cancer Diagnosis 2Health News:One Gene May Be Key to Myeloma 2Health News:One Gene May Be Key to Myeloma 3Health News:Almost Family, Inc. Set to Join to Russell 2000(R) Index 2Health News:Bat Scan to the Rescue: New Clubhouse CT Scanner Helps Eliminate Exploding Bats 2Health News:Bat Scan to the Rescue: New Clubhouse CT Scanner Helps Eliminate Exploding Bats 3
...
...
... FLEXILOG antimony pH catheters are designed for ... ,All catheters are number marked at 5cm ... ,More than sixteen individual models are available spanning ... single-use or multi-use models with one or two ...
... are designed using established technology providing ... benefits:, ,Working with pH catheters ... the multi-use catheter is used the ... to the skin.,NOTE: ,Medtronic pH measurement ...
Medicine Products: